Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy

Cancer Immunology, Immunotherapy · Published 2017-08-01 · Available online 27 Apr 2017 · Journal article · DOI 10.1007/s00262-017-2003-1 · Cited by 223 (Crossref)

Authors (3)

Hong Jiang, Samarth Hegde, David G. DeNardo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

66

Issue

8

Pages

1037-1048

Year

2017

Citation

Jiang, H., Hegde, S., DeNardo, D. (2017). Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-017-2003-1

Related articles

• Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion · Cancer Communications · 2026 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

223